​

Cabaletta Bio (CABA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CABA Stock Forecast

Cabaletta Bio (CABA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $16.33, with a high of $32.00 and a low of $3.00. This represents a 1384.55% increase from the last price of $1.10.

- $7 $14 $21 $28 $35 High: $32 Avg: $16.33 Low: $3 Last Closed Price: $1.1

CABA Stock Rating

Cabaletta Bio stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

CABA Price Target Upside V Benchmarks

TypeNameUpside
StockCabaletta Bio1384.55%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.10$1.10$1.10
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25282--12
Mar, 25282--12
Feb, 25282--12
Jan, 25282--12
Dec, 242102--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 21, 2024Ben BurnettStifel Nicolaus$32.00$17.5482.44%2809.09%
Jan 03, 2023Wells Fargo$14.00$9.3050.54%1172.73%
Aug 30, 2022Michael UlzMorgan Stanley$3.00$1.26138.10%172.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2024UBSBuyinitialise
Sep 17, 2024H.C. WainwrightBuyBuyhold
Apr 29, 2024CitigroupBuyBuyhold
Apr 04, 2024CitigroupBuyBuyhold
Nov 15, 2023Cantor FitzgeraldOverweightOverweighthold
Jul 18, 2023GuggenheimBuyinitialise
Jan 03, 2023Wells FargoOverweightOverweighthold
Sep 14, 2022Wells FargoOverweightOverweighthold
Aug 30, 2022Morgan StanleyOverweightdowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.65$-2.34----
Avg Forecast$-1.61$-2.34$-2.54$-2.65$-2.39$-1.71
High Forecast$-1.55$-2.30$-1.97$-1.67$-0.54$-1.71
Low Forecast$-1.69$-2.41$-2.93$-3.82$-3.82$-1.71
Surprise %2.48%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$6.25M$1.88M$76.00M$288.67M
High Forecast--$6.25M$1.88M$76.00M$288.67M
Low Forecast--$6.25M$1.88M$76.00M$288.67M
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-67.67M$-115.86M----
Avg Forecast$-67.67M$-96.37M$-100.34M$-112.28M$-89.33M$-69.88M
High Forecast$-63.38M$-94.12M$-80.79M$-68.23M$-22.28M$-69.88M
Low Forecast$-69.18M$-98.62M$-119.89M$-156.33M$-156.38M$-69.88M
Surprise %-20.22%----

CABA Forecast FAQ

Is Cabaletta Bio stock a buy?

Cabaletta Bio stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cabaletta Bio is a favorable investment for most analysts.

What is Cabaletta Bio's price target?

Cabaletta Bio's price target, set by 10 Wall Street analysts, averages $16.33 over the next 12 months. The price target range spans from $3 at the low end to $32 at the high end, suggesting a potential 1384.55% change from the previous closing price of $1.1.

How does Cabaletta Bio stock forecast compare to its benchmarks?

Cabaletta Bio's stock forecast shows a 1384.55% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Cabaletta Bio over the past three months?

  • April 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Cabaletta Bio’s EPS forecast?

Cabaletta Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.54, marking a 8.55% increase from the reported $-2.34 in 2024. Estimates for the following years are $-2.65 in 2026, $-2.39 in 2027, and $-1.71 in 2028.

What is Cabaletta Bio’s revenue forecast?

Cabaletta Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $6.25M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $1.88M, followed by $76M for 2027, and $288.67M for 2028.

What is Cabaletta Bio’s net income forecast?

Cabaletta Bio's net income forecast for the fiscal year ending in December 2025 stands at $-100M, representing a -13.40% decrease from the reported $-116M in 2024. Projections indicate $-112M in 2026, $-89.334M in 2027, and $-69.884M in 2028.